Posted by Michael Wonder on 24 Feb 2022
FDA grants BI 1015550 breakthrough therapy designation for idiopathic pulmonary fibrosis
24 February 2022 - Designation is supported by Phase II efficacy and safety data that will be presented at ATS 2022.
Boehringer Ingelheim announced today that the U.S. FDA granted breakthrough therapy designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis.
